pathology home page
Headshot of Konstantin Shilo
Konstantin Shilo, MD

E412 Doan Hall
410 W. 10th Ave
Columbus, OH 43210
Link to director's bio

Center of Excellence of Thoracic Pathology

Thoracic Pathology actively participates in Multidisciplinary Conferences (Tumor Boards) providing a critical role in treatment decision-making. Our education mission involves lecturing to residents and fellows inside and outside of the department. The faculty members continue to work closely with other departments within the College of Medicine to establish collaborative research efforts in the biology of lung cancer and interstitial lung disease. These research efforts have resulted in publications and grant awards.

CURRENT COLLABORATIONS / GRANT SUPPORT

Project Title:

Tri-State SenNET lung and heart tissue map and atlas consortium
(Finkel/Koenigshoff/Mora/Rahman)
University of Pittsburgh (NIA/NIH; U54AG075931)

Project Title:

Overcoming hypoxic resistance in non-small cell lung cancer (NSCLC) by targeting mitochondrial metabolism
(Denko/Li/Terence)
NCI/NIH (R01CA262388)

Project Title:

Appalachian and Great Lakes research biospecimen resource (AGL-RBR) of the cooperative human tissue network (CHTN)
(Parwani)
NCI/NIH (UM1CA239749)

OSU Conferences / Lectures

  • Thoracic Tumor Board, weekly
  • Interstitial Lung Disease Conference, bi-weekly
  • Pathology Residents
  • Pulmonary and Critical Care Disease Fellows

Collaborations

  • OSU Lung Cancer Center (Dr. David Carbone)
  • OSU Molecular Pathology, Lung Cancer Profiling (Dr. Dan Jones)
  • Interstitial Lung Disease Clinic (Dr. Derrick Herman)
  • OSU Autopsy Services (Dr. Saman Ahmadian)
  • Radiation Oncology (Dr. Jeremy Brownstein)
  • Lung transplantation (Dr. Bryan Whitson, Dr. David Nunley)

Prior Grant Support/OSU Translational and Basic Research Programs

• OSU-20222 (ML41591): NAUTIKA1: Multicenter, Phase II, Neoadjuvant and Adjuvant Study of Alectinib, Entrectinib, Vemurafenib Plus Cobimetinib, or Pralsetinib in Patients with Resectable Stages II-III Non-Small Cell Lung Cancer with ALK, ROS1, NTRK, BRAF V600, or RET Molecular Alterations (Dr. Kai He)

• OSU-21139 (IOV-LUN-202): A Phase II Multicenter Study of Autologous Tumor Infiltrating Lymphocytes (LN-145) in Patients with Metastatic Non-Small-Cell Lung Cancer (Dr. Kai He)

• OSU-20222 (ML41591): NAUTIKA1: Multicenter, Phase II, Neoadjuvant and Adjuvant Study of Alectinib, Entrectinib, Vemurafenib Plus Cobimetinib, or Pralsetinib in Patients with Resectable Stages II-III Non-Small Cell Lung Cancer with ALK, ROS1, NTRK, BRAF V600, or RET Molecular Alterations (Dr. Kai He)

• OSU-21139 (IOV-LUN-202): A Phase II Multicenter Study of Autologous Tumor Infiltrating Lymphocytes (LN-145) in Patients with Metastatic Non-Small-Cell Lung Cancer (Dr. Kai He)

• OSU-22287: A Phase I/II, Open-Label Study of PD-1 Knockout Tumor-Infiltrating Lymphocytes (IOV-4001) in Participants with Unresectable or Metastatic Melanoma or Stage III or IV Non-Small-Cell Lung Cancer (Dr. Kai He)

• OSU-16157 (ML39236): A phase II, open-label, multicentric, single-arm study to investigate the efficacy abd safety of Atezolizumab as neoadjuvant and adjuvant therapy in patients with Stage IB, II, OR IIIA resectable and untreated non-small cell lung cancer (Dr. Dwight Owen)

• Role of Notch3 in EGFR mutant lung tumors before and after EGFR blockade (Dr. Raj Arasada; Dr. David Carbone)

• EGFR, Notch3 and beta-catenin axis in cancer stem cells (Dr. Raj Arasada)

• Genomic predictors of metastasis: Comparison of primary and brain metastatic cancers of patients with Non-Small Cell Lung Cancer blockade (Dr. Joseph Aman; Dr. David Carbone)

• Finding biomarkers to determine response in NSCLC and melanoma patients treated with anti-PD1 or anti-PDL1 immunotherapy (Dr. Joseph Aman; Dr. David Carbone)

• Clinical Outcomes and Molecular Correlates of Patients Who Have Received Radiation for Lung Cancer (Dr. Terry Williams)

• Role of PRMT5 in solid tumors (Dr. Robert Baiocchi)

• Proteomic signatures of solid tumors (Dr. Michael Freitas)

• Chemokine receptor CCR5: Novel target for inhibiting lung cancer growth and metastasis (Dr. Ramesh Ganju)

• TRPV2/Cannabidiol: A novel therapeutic target and strategy against aggressive and metastatic breast cancer (Dr. Ramesh Ganju)

• FABP5 as a novel therapeutic target against aggressive lung cancer (Dr. Ramesh Ganju)

• Crosstalk between microRNA-1 and CXCR4 in small cell lung cancer growth and drug resistance (Dr. Mohd Nasser; Dr. Ramesh Ganju)

• Targeting somatic homologous recombination in solid tumors (Dr. Miguel Villalona; Dr. Sameh Mikhail)

• The pivotal role of macrophages in regulating pulmonary fibrosis (Dr. Megan Ballinger)